NCT07095361View on ClinicalTrials.gov

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Pleural Infection BacterialPleural InfectionsPleural Infections and InflammationsEmpyema, PleuralEmpyemaComplicated Pleural Effusion/ EmpyemaPleural Effusion Associated With Pulmonary InfectionPleural Effusion
Interventions
DRUG

Fibrinolytic once daily

tissue plasminogen activator (tPA) 10mg will be administered once a day as part of intrapleural enzyme therapy (IET) for 3 consecutive days.

DRUG

Fibrinolytic twice daily

tissue plasminogen activator (tPA) 10mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.

DRUG

DNA degradation once daily

Deoxyribonuclease (DNase) 5mg will be administered once a day as intrapleural enzyme therapy (IET) for 3 consecutive days.

DRUG

DNA degradation twice daily

Deoxyribonuclease (DNase) 5mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.

Trial Locations (1)

27514

UNC Chapel Hill, Chapel Hill

All Listed Sponsors
lead

University of North Carolina, Chapel Hill

OTHER

NCT07095361 - Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema | Biotech Hunter | Biotech Hunter